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Abstract
Links between the gut microbiota and host metabolism have provided new perspectives on obesity. We previously showed
that the link between the microbiota and fat deposition is age- and time-dependent subject to microbial adaptation to diet
over time. We also demonstrated reduced weight gain in diet-induced obese (DIO) mice through manipulation of the gut
microbiota with vancomycin or with the bacteriocin-producing probiotic Lactobacillus salivarius UCC118 (Bac+), with
metabolic improvement achieved in DIO mice in receipt of vancomycin. However, two phases of weight gain were observed
with effects most marked early in the intervention phase. Here, we compare the gut microbial populations at the early
relative to the late stages of intervention using a high throughput sequencing-based analysis to understand the temporal
relationship between the gut microbiota and obesity. This reveals several differences in microbiota composition over the
intervening period. Vancomycin dramatically altered the gut microbiota composition, relative to controls, at the early stages
of intervention after which time some recovery was evident. It was also revealed that Bac+ treatment initially resulted in the
presence of significantly higher proportions of Peptococcaceae and significantly lower proportions of Rikenellaceae and
Porphyromonadaceae relative to the gut microbiota of L. salivarius UCC118 bacteriocin negative (Bac-) administered
controls. These differences were no longer evident at the later time. The results highlight the resilience of the gut
microbiota and suggest that interventions may need to be monitored and continually adjusted to ensure sustained
modification of the gut microbiota.
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Introduction
Obesity is due to a surplus of energy intake over expenditure,
resulting in storage of excess energy as fat. However, this is only
part of a bigger story; an emerging theme is the relationship
between the composition and functionality of microorganisms in
the gut with obesity. [1,2,3,4,5] A corollary to this is the potential
for manipulation of the gut microbiota in the prevention and
management of obesity and associated metabolic disorders.
We previously showed that compositional changes in the
faecal microbiota associated with diet-induced obesity are time-
dependent and unrelated to markers of energy harvest, which
change over time. [6] Furthermore, we have previously
investigated the impact of administering the glycopeptide
antibiotic vancomycin and the bacteriocin-producing probiotic
Lactobacillus salivarius UCC118 (Bac+) to diet-induced obese
(DIO) mice. Vancomycin resulted in an improvement in the
metabolic abnormalities associated with obesity, including a
significant reduction in weight gain, by the end of the
intervention period. In contrast, when compared with an
isogenic non-bacteriocin producing control (Bac-), the L.
salivarius UCC118 Bac+ strain alters the gut microbiota but
did not significantly alter metabolic markers or weight gain as
measured at the end of the intervention period. [7].
While our initial report focused on the metabolic changes
evident upon completion of the intervention strategies, the
temporal changes in the microbiota need to be addressed further.
The impact of vancomycin intervention on weight gain was most
considerable during the early stages of intervention and a
significant reduction in weight gain in mice fed with the Bac+
strain was apparent when compared with their Bac- fed
counterparts. [7] Here, we analyse and compare the gut microbial
populations of these animals at the early (week 2) with the late
(week 8) intervention period. The results reflect the resilience of
the gut microbiota and show that therapeutic manipulation of the
microbiota is likely to be more complex than anticipated with
sustained adjustment likely to require multiple interventions over
time.
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Materials and Methods
Animals
3–4 week old male C57BL/6j mice were acquired from Harlan
(oxon, UK) and housed within the biological services unit,
University College Cork. UCC Animal Ethics Committee
approved all experiments and experimental procedures were
conducted under licence from the Irish government.
Experimental Design
A low fat (lean) or high fat (DIO) diet was fed to male C57BL/J6
mice (aged 7 weeks) for 12 weeks followed by an intervention
period during which the high fat diet was supplemented with the
glycopeptide antibiotic vancomycin, the bacteriocin producing
(Bac+) L. salivarius UCC118, its bacteriocin negative derivative
(Bac–) or was unsupplemented (9–10 mice/cohort) for a period of
8 weeks. For full experimental design see figure S1 and Murphy
et al. [7].
DNA extraction and High-throughput Amplicon
Sequencing
Individual mouse faecal samples were collected and DNA was
extracted on the same day of collection from fresh samples using
the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex,
UK) combined with an additional bead-beating step (30 s63) and
stored at 220uC. The microbiota composition of the samples was
established by amplicon sequencing; universal 16 S rRNA primers
estimated to bind to 94.6% of all 16 S genes (i.e. the forward
primer F1 (59-AYTGGGYDTAAAGNG) and a combination of
four reverse primers R1 (59-TACCRGGGTHTCTAATCC), R2
(TACCAGAGTATCTAATTC), R3 (59-CTACDSRGGTMTC-
TAATC) and R4 (59-TACNVGGGTATCTAATC) (RDP’S
Pyrosequencing Pipeline: http://pyro.cme.msu.edu/pyro/help.
jsp) were employed for PCR amplification. Molecular identifier
tags were attached between the 454 adaptor sequence and the
target-specific primer sequence, allowing for identification of
individual sequences from the pooled amplicons. Ampure
purification system (Beckman Coulter, Takeley, UK) was used to
clean the amplicons before being sequenced on a 454 Genome
Sequencer FLX platform (Roche Diagnostics Ltd, Burgess Hill,
West Sussex, UK) in line with 454 protocols at the Teagasc high
throughput sequencing centre. The amplicon sequences were
deposited in the European bioinformatics institute sequence read
archive (EBI-SRA) accession number ERP002448.
Real Time Quantitative PCR
Total bacterial numbers (16 S rRNA gene copies per gram of
wet stool) [8] were determined using real time quantitative PCR.
The 16 S rRNA gene sequence of E. coli EPI300 was amplified
using the universal 16 S primers 802R and 520F. [9] The
amplified products purified using the High Pure PCR Cleanup
Micro Kit (Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK)
were inserted into the pCR4-TOPO Vector (Invitrogen, Bio-
Sciences, Dublin Ireland) and transformed into One Shot TOP10
Chemically Competent E. coli (Invitrogen, Bio-Sciences, Dublin,
Ireland). Plasmids were extracted using the PureYieldTM Plasmid
Miniprep System (Promega, Madison, Wisconsin, USA) and
quantified on the NanoDropTM 1000 Spectrophotometer
(Thermo Fisher Scientific, Waltham, Massachusetts, USA).
Quantitative real time PCR (QPCR) was performed with
SYBER-green (Roche Diagnostics Ltd, Burgess Hill, West Sussex,
UK) on the lightcycler 480 (Roche Diagnostics Ltd, Burgess Hill,
West Sussex, UK). The standard curve was generated using
dilutions of the plasmid DNA. The following program was used to
quantify total bacterial numbers: 95uC for 5 min followed by 40
cycles of 95uC for 20 s, 51uC for 20 s and 72uC for 20 s followed
by melting curve analysis of 95uC for 5 s, 46uC for 1 min, and
97uC continuously and a final cooling at 40uC for 10 s. Samples
contained 2 ml of PCR grade water, 1 ml of 520F (0.15 mM), 1 ml
of the 802R (0.15 mM), 1 ml template DNA, and 5 ml of SYBR
green. Samples and standards were run in triplicate. Negative
controls were added to each plate with template DNA being
replaced with PCR-grade water. The copy numbers of each
sample were calculated from the standard curve and copies of 16 S
rRNA/g wet stool was calculated using a previously outlined
calculation. [8].
Bioinformatics Sequence Analysis
A locally installed RDP pyrosequencing pipeline was used to
quality trim the raw sequence data. Reads were removed that were
shorter than the main distribution (150 bp for the 16 S rRNA V4
region), of low quality and not exact matches to barcoded tags and
primer sequence. A locally installed version of SILVA 16 S rRNA
database [10] was used to BLAST [11] the trimmed fasta sequence
files using default parameters. Resulting BLAST output files were
parsed through Megan [12] which uses a lowest common ancestor
algorithm to assign reads to NCBI taxonomies. Prior to tree
construction and summarization filtering was carried out within
MEGAN using bit scores, similar to previous studies a bit-score
cut-off of 86 was selected. [13,14] Alpha diversity indices were
generated using MOTHUR software. [15] Clustering of sequence
reads into operational taxonomical units (OTUs) at 97% identity
was achieved using QIIME suite software tools. [16] The
ChimeraSlayer program was used to remove chimeric OTUs
from aligned OTUs and the FastTreeMP tool generated a
phylogenetic tree. [17,18] Beta diversities were also calculated
on the sequence reads based on weighted and unweighted unifrac
and bray curtis distances; subsequently principal coordinate
analysis (PCoA) and unweighted pair group method with
arithmetic mean (UPGMA) clustering was performed on the
samples. UPGMA clustering was visualised using Dendroscope
software [19] while PCoA plots were viewed with KiNG viewer.
[20] The nonparametric Kruskal-Wallis test [21] in the Minitab
statistical package was employed to establish statistical significance
(significance taken to be p#0.05).
Results
a Diversity of the Murine Gut Microbiota Increases
During the Intervention Period
There is a significant reduction in weight gain in DIO mice at
intervention weeks 2–4 (early intervention period) in the Bac+
intervention, when compared to Bac- intervention, but this does
not persist with time (Figure 1A). [7] Vancomycin administration
results in a two phase reduction in weight gain in DIO mice. In
phase one (early intervention weeks 1–4) a significant reduction in
weight gain relative to the initial start weight is observed. In the
second phase, DIO mice receiving vancomycin gain weight
relative to the initial start weight but weight change continues to
be significantly less than that in DIO controls (Figure 1B). [7] The
relationship between these early intervention period-specific
observations and the gut microbiota were investigated through
high throughput DNA sequencing. A total of 86,103 V4 16 S
sequence reads, corresponding to faecal pellets from mice at
intervention week 2 of the study, were generated. These
corresponded to an average of 14,978 reads per group or
1,757 per mouse. These reads were analysed and compared with
212,655 16 S sequence reads generated from the mice at
Targeting Microbiota to Address Obesity
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intervention week 8. [7] Shannon diversity, simpson diversity and
species richness estimations were calculated for each data set
(Figure 2). The Chao1 estimator of species richness reveals
significant differences in species richness with time in all
populations, including lean and DIO animals not exposed to
interventions. Shannon diversity data revealed a high level of
biodiversity in all groups along with a significant increase in
diversity with time in all cohorts except those in receipt of a lean
diet only (Figure 2). The Simpson diversity index-based analysis,
which also takes account the number of species present and the
relative abundance of each species, particularly highlighted the
significant increase in diversity in animals in receipt of vancomycin
as the intervention period continued. Thus while a general
increase in gut microbial diversity was apparent as the mice aged,
it was apparent that exposure to vancomycin brought about an
initially considerable reduction in diversity which was diminished
with time. Goods coverage ranged between 95% and 98% at week
2 and from 84% to 86% at week 8. Rarefaction curves were seen
to be approaching parallel or parallel (Figure S2) signifying that
extra sampling would yield a limited increase in species richness.
Of the reads at week 2, 74,686 (87%) were assigned at phylum
level, 59,720 (69%) at the family level and 40,947 (48%) at genus
level.
Taxonomical Analysis Highlights the Temporal Impact of
Vancomycin on Specific Components of the Gut
Microbiota
Analysis of the gut microbiota composition after 2 weeks
established that the major difference, at the phylum level, between
the microbiota of the lean and diet induced obese (DIO) mice is
the presence of relatively greater proportions of Firmicutes and
relatively lower proportions of Bacteroidetes in DIO mice when
compared with lean mice (p-value #0.05). At family level,
significantly greater proportions of Rhodospirillaceae, Lachnospiraceae,
Streptococcaceae, Lactobacillaceae, and Clostridiaceae in DIO mice were
apparent when compared to lean mice (p value #0.05), whereas
significantly lower proportions of Alcaligenaceae, Rikenellaceae, Bacte-
roidaceae and Coriobacterineae were evident when DIO mice were
compared with lean mice (p value#0.05). At genus level, when the
microbiota of DIO mice were compared with that of lean mice,
significantly more, Thalassospira, Alistipes, Odoribacter and Bacteroides
and significantly less Sutterella Lactococcus, Turicibacter, Lactobacillus,
Clostridium and Anaeroplasma were observed (p value#0.05; Figure 3
& Table S1 in File S1).
High-throughput DNA sequence based analysis of the gut
microbiota at week 2 also revealed statistically significant
differences at phylum level between DIO and DIO vancomycin
treated mice. Significant decreases in proportions of Bacteroidetes
and Deferibacteres (p value #0.05), but not Firmicutes, were
noted in vancomycin treated DIO mice compared with DIO mice.
An increase in proportions of Proteobacteria (p value #0.05) in
DIO vancomycin treated mice was also evident. At family level,
proportions of Rhodospirillaceae, Rikenellaceae, Porphyromonadaceae,
Bacteroidaceae, Ruminococcaceae, Peptostrepococcaceae, Peptococcaceae, Er-
ysipelotrichaceae, and Deferribacteraceae (p value #0.05) were all
relatively lower in the vancomycin treated mice relative to DIO
controls whereas proportions of Alcaligenaceae, Enterobacteriaceae,
Streptococcaceae, Lactobacillaceae and Leuconostocaceae (p value #0.05)
were all relatively greater in the former group. At genus level
relatively lower proportions of Thalassospira, Alistipes, Rikenella,
Parabacteroides, Odoribacter, Bacteroides, Lachnospiraceae Incertae Sedis,
Coprococcus, Ruminococcaceae Incertae Sedis, Oscillibacter, Anaerotruncus,
Turicibacter, Allobaculm, Mucispirillum, uncultured Lachnospiraceae
genus members, Peptostreptococcaceae Incertae Sedis, Peptococcus, Clos-
tridium and Anaeroplasma (p value #0.05) were detected in DIO
vancomycin treated mice compared with DIO mice. These were
accompanied by the presence of relatively greater proportions of
Sutterella, Lactococcus, Lactobacillus, Weissella and members of
Enterobactereaceae-associated genera in the antibiotic treated group
(p value #0.05) (Figure 3 & Table S1 in File S1).
The sequence data generated was investigated from a temporal
perspective. As suggested from a diversity values, the six weeks
which passed from intervention week 2 to 8 of the study impacted
on microbiota composition even in animals where no intervention
occurred, i.e. the lean and DIO controls, presumably as a
consequence of the aging of the animals. At week 8, among the
lean animals, it was noted that significant increases in proportions
of the phyla Deferribacteres and Verrucomicrobia (p value #0.05)
occurred and, at family level, the relative proportions of
Rhodospirillaceae, Desulfovibrionaceae, Deferribacteraceae, Lactobacillaceae,
Verrucomicrobiaceae and Eubacteriaceae (p value #0.05) were all
significantly increased when compared with microbiota from the
same animals at week 2. At genus level proportions of Thalassospira,
Desulfovibrio, Allobaculm, Mucispirillum, Lactobacillus, Akkermansia,
Bilophila and Blautia (p value #0.05) all increased between weeks
2 and 8. In contrast, proportions of Bacteroidetes (phylum, p value
#0.05), Porphyromonadaceae, Bacteroidaceae, Ruminococcaceae (family, p
value #0.05) and Alistipes, Bacteroide, Coprococcus and Ruminococcaceae
Incertae Sedis (genus, p value #0.05) all decreased between the two
time points.
Among DIO mice there were relative increases in the
proportions of Proteobacteria, Actinobacteria, Deferribacteres
and Verrucomicrobia (p value #0.05) at the week 8, relative the
week 2 time point. This corresponded to significant increases in
Rhodospirillaceae, Desulfovibrionaceae, Bifidobacteriaceae, Deferribacteraceae
and Verrucomicrobiaceae at the family level (p value #0.05) and
Desulfovibrio, Mucispirillum, uncultured Lachnospiraceae, Akkermansia,
Bilophila and Catabacter (p value #0.05) at the genus level. In
contrast, proportions of Ruminococcaceae, Clostridiaceae (p value
#0.05) and Coprococcus, Ruminococcaceae Incertae Sedis, Turicibacter
and Clostridium decreased between the two time points (p value
#0.05).
Comparison of the impacts of vancomycin treatment at week 2
relative to those at week 8 had the potential to be particularly
revealing given that the relative extent to which the antibiotic
impacted on weight gain was greater at the earlier time point and
that a diversity also increased during the intervening period. This
suggested that a compensatory effect, possibly due to the recovery
of specific populations, occurred between the two time points.
Analysis revealed that several taxa increased in relative propor-
tions during this interval. These included Bacteroidetes, Actino-
bacteria, Defferibacteres and Verrucomicrobia (p value #0.05) at
the phylum level, Desulfovibrionaceae, Rikenellaceae, Porphyromonadaceae,
Ruminococcaceae, Erysipelotrichaceae, Bifidobacteriaceae, Deferribacteraceae,
Verrucomicrobiaceae and Enterobacteriaceae (p value #0.05) at the
family level and Ruminococcaceae Incertae Sedis, Turicibacter, Clostridium,
Akkermansia, Allobaculum, Desulfovibrio, Alistipes, Bifidobacterium, Mucis-
pirillum, Anaeroplasma and members of Enterobacteriaceae-associated
genera (p value #0.05) at the genus level. Of the genus level
changes, only the Ruminococcaceae Incertae Sedis, Turicibacter, Clostrid-
ium and Akkermansia associated changes corresponded with
temporal changes which were evident in the DIO control group
and thus the other genera which underwent relative increases in
proportions likely represent the populations which have most
successfully adapted to vancomycin exposure. Within the vanco-
mycin treatment group the only phylum to decrease significantly,
from a temporal perspective, in the gut microbiota of the
vancomycin administered mice was the Firmicutes (p value
Targeting Microbiota to Address Obesity
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#0.05), which corresponded with a significant decrease in the
relative proportions of the family Streptococcaceae (p value #0.05)
and the genus Lactococcus (p value #0.05). A significant decrease
over time was also apparent within the genus Weissella (p value
#0.05) (Table S1 in File S1).
UCC118 Bac+ associated reductions in weight gain correspond
to reductions in Rikenellaceae and Porphyromonadaceae and
increases in Peptococcaceaepopulations.
While the impact of vancomycin administration on weight gain
decreased from intervention week 2 to week 8 of the study, this
impact continued to be significant throughout. However, the
impact on weight gain of employing the bacteriocin producing
probiotic relative to its isogenic non-bacteriocin producing
equivalent changed from being significant to non-significant over
the same duration. Comparison of the impact of the two strains at
week 2 revealed no significant differences at the phylum level
between the two groups. However, at family level, a relative
decrease in proportions of Rikenellaceae and Porphyromonadaceae (p
value #0.05) was noted in Bac+ mice relative to their Bac-
counterparts. At genus level, a relative reduction was observed in
Alistipes (p value #0.05) in Bac+ mice compared with Bac- mice.
Furthermore, a relative increase in proportions of the family
Peptococcaceae (p value #0.05) and the corresponding genus
Peptococcus (p value #0.05) was noted in Bac+ mice compared
with Bac- mice (Figure 4 & Table S2 in File S1).
Continued exposure to the bacteriocin producing UCC118
strain brought about a variety of changes. At phylum level the
relative proportions of Firmicutes, Candidate Division TM7,
Deferribacters and Verrucomicrobia (p value #0.05) were
significantly increased by week 8. Proportions of the families
Desulfovibrionaceae, Erysipelotrichaceae, Deferribacteraceae, Verrucomicrobia-
ceae and Eubacteriaceae (p value #0.05) and the genera Desulfovibrio,
Lactococcus, Akkermansia, Clostridium, Bilophila, Mucispirillum, Turici-
bacter and Catabacter (p value #0.05) also increased. Over the same
period relative reductions in the phylum Bacteroidetes (p value
#0.05), the families Rikenellaceae, Porphyromonadaceae and Bacteroida-
Figure 1. Delta weight gain over the eight week intervention period. (A) Bac+ intervention, when compared to Bac- intervention, causes a
significant reduction in weight gain in diet induced obese mice at weeks 2–4 (early intervention period) but this does not persist with time. (B)
Vancomycin treatment results in a two phase reduction in weight gain in diet induced obese mice. In phase one (early; weeks 1–4) a significant
reduction in weight gain relative to the initial start weight is observed. In the second phase, diet induced obese mice receiving vancomycin gain
weight relative to the initial start weight but weight change continues to be significantly less than that in diet induced obese controls. Data
represented as mean SEM n= 9–10 *p,0.05.
doi:10.1371/journal.pone.0065790.g001
Targeting Microbiota to Address Obesity
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Figure 2. a diversity of the gut microbiota within each time point. In a number of instances significant increases in diversity are observed
between intervention week 2 and week 8. Statistical significance was determined by kruskal wallis. * Statistical significant difference (p,0.05). Data
represented as mean6SEM (n= 9–10).
doi:10.1371/journal.pone.0065790.g002
Figure 3. Microbial distribution at phylum level. Phylum level microbial distribution in all data sets at intervention week 2 and week 8. The pie
charts represent total percentage read number for the corresponding colour coded phylum (n= 9–10 per group).
doi:10.1371/journal.pone.0065790.g003
Targeting Microbiota to Address Obesity
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ceae (p value #0.05) as well as the genera Alistipes, Parabacteroides
and Bacteroides (p value #0.05) also occurred (Figure 4 & Table S2
in File S1).
The impact of administering the bacteriocin negative UCC118
strain also changed between the two time points. At phylum level
relative increases in the proportions of the Firmicutes, Actino-
bacteria and Candidate Division TM7 (p value #0.05) were seen
which corresponded with increases at family level in Desulfovi-
brionaceae, Lachnospiraceae, Peptococcaceae, Erysipelotrichaceae, Bifidobac-
teriaceae, Coriobacterineae and Lactobacillaceae (p value #0.05). At
genus level increases in Desulfovibrio, Turicibacter, Bifidobacterium,
uncultured Lachnospiraceae, Peptococcus, Bilophila and Catabacter (p
value #0.05) were also noted. Relative reductions in the phylum
Bacteroidetes (p value #0.05), families Rikenellaceae, Porphyromona-
daceae and Bacteroidaceae (p value #0.05) as well as the genera
Alistipes, Rikenella, Parabacteroides and Bacteroides (p value #0.05)
also occurred (Figure 4 & Table S2 in File S1). It should also be
noted that the proportions of Rikenellaceae, Porphyromonadaceae and
Peptococcaceae in Bac+ fed mice relative to that in Bac– fed controls
did not differ significantly at the later time point (intervention
week 8).
Vancomycin Administration Reduces Total Bacterial
Numbers in the Gut
As high throughput sequencing reveals information with respect
to relative proportions of populations rather than relative
numbers, quantitative PCR was employed to determine if the
antimicrobial employed, i.e. vancomcyin or the bacteriocin
Abp118, impacted on the total number of gut microbes present.
Analysis revealed that there were no significant differences in total
bacterial numbers in the faeces of diet induced obese mice
compared with lean controls (p,0.96) at week 2. While treatment
of the diet-induced obese mice with vancomycin resulted in a
decrease in absolute faecal bacteria compared with their diet-
induced obese counterparts (P,0.006 Figure 5), bacteriocin
production did not alter the total bacterial numbers in the diet
induced obese mice. The significant impact of vancomycin, but
not other interventions, on total bacterial counts is also apparent at
week 8. [7].
Beta Diversity Highlights Temporal Variation in Microbial
Populations
Principal coordinate analysis (based on unweighted unifrac
distances) of the 16 S rRNA sequences further highlights the
temporal changes in the microbial populations from intervention
week 2 to 8 with samples clearly clustering according to time point
(Figure 6). In line with the a diversity and taxonomical data
presented above, it is apparent that data points corresponding to
DIO mice who received vancomycin (purple) cluster away from
those corresponding to the other groups. The degree to which
these data points are removed is more apparent at week 2, again
suggesting that a recovery occurs during the subsequent weeks
(Figure 6). At week 8, data points corresponding to the DIO
controls (red) cluster tightly together within a larger cluster. Such
tight clustering is not apparent at week 2 (Figure 6). It would also
appear that the Bac+ (green) and Bac- (orange) mice are more
distinct at week 2 (Figure 6). Hierarchical clustering of the OTUs
from each dataset also highlights the temporal instability in the
mouse microbiota between the two time points. However the
unweighted pair group method with arithmetric mean (UPGMA)
tree shows that, at specific time points, the microbiota of mice
within each treatment group are generally more similar to each
other than they are to those from the other groups (Figure S3).
Hierarchical clustering again highlights the separation of the
vancomycin-exposed populations from the other groups. In
addition to clustering away from the other groups, it is also clear
that these populations differ at the respective time points. At week
8, the ‘lean’ OTUs cluster into two groups on either side of the
DIO OTUs, this separation was not observed at week 2. No
significant difference in weight was observed between these
Figure 4. Microbial distribution at family level. Family level microbial distribution in all data sets at intervention week 2 and week 8. The pie
charts represent total percentage read number for the corresponding colour coded family (n= 9–10 per group).
doi:10.1371/journal.pone.0065790.g004
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respective lean subgroups. At week 2 Bac+ OTUs are divided into
two groups on either side of DIO OTUs. This separation did not
persist with time.
Discussion
This analysis of the gut microbiota of animals subjected to either
vancomcyin or the bacteriocin producing probiotic L. salivarius
UCC118 intervention provides valuable information regarding the
temporal nature of the resultant changes. The results reflect
microbial adaptation over time and the resilience of the
microbiota. Principal coordinate analysis (PCoA) and hierarchical
clustering analysis reveal that clustering occurs as a feature of time
and to a lesser extent, treatment groups, rather than between
microbial populations from within the same animal. In agreement
with previous studies, [22,23,24] we established that the diet-
Figure 5. Total bacterial number observed in all treatment groups at both time points. Quantitative PCR reveals that the changes
occurring are qualitative not quantitative as no significant difference is observed between time points. Total bacterial numbers calculated as copies of
16 S rRNA/g wet stool. Statistical significant difference between treatment groups is denoted by ***. p value based on kruskal wallis analysis with
statistical significant determined as p#0.05. Error bars represent the standard error of the mean.
doi:10.1371/journal.pone.0065790.g005
Figure 6. Principal coordinate analysis of unweighted unifrac reveals temporal shift. Vancomycin treated diet induced obese mice
(purple) cluster away from other groups at both time points, however the distance between these mice and other treatment groups at week 8 is less
than at week 2. Data sets: purple vancomycin, blue lean, red DIO, green Bac+ and orange Bac-.
doi:10.1371/journal.pone.0065790.g006
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induced obesity-associated murine gut microbiota differed from
that of lean controls. More specifically, a significant increase in the
proportion of Firmicutes and a decrease in the proportion of
Bacteroidetes. Vancomycin was selected because of its limited
systemic impact and its apparent ability to specifically target the
low GC Gram-positive organisms i.e. Firmicutes. [7] Here, we
establish that treatment of mice on a high fat diet with vancomycin
resulted in significant alterations in the composition of the gut
microbiota; including a decrease in the relative proportions of
Bacteroidetes and Deferribacteres and a relative increase in the
proportions of Proteobacteria relative to DIO controls. This
vancomycin-induced effect on Proteobacteria populations has
been noted before. [25,26] In contrast to week 8, the proportion of
Firmicutes was not reduced between animals receiving vancomy-
cin and controls at intervention week 2. At this time point, the
corresponding increased proportions of the families Streptococcaceae,
Lactobacillaceae and Leuconostocaceae (all members of the Firmicutes
phylum) might negate the detrimental impact of vancomycin on
other Firmicutes members, resulting in the absence of an overall
net change. The glycopeptide antibiotic vancomycin is tradition-
ally known to be active against Gram-positive bacteria such as
Staphylococcus aureus and Clostridium difficile through the inhibition of
cell wall synthesis. [25,27,28] The cell wall of Gram-negative
bacteria is protected by the presence of an outer membrane that
blocks the effects of vancomycin. [29] Nevertheless, here we found
that eight genera (Thalassospira, Alistipes, Rikenella, Parabacteroides,
Odiorbacter, Bacteroides, Oscillibacter and Mucispirillum) of Gram-
negative bacteria were significantly reduced in vancomycin treated
DIO mice at week 2. Also three Gram-positive genus (Lactococcus,
Lactobacillus and Weissella) increased at week 2 in vancomycin
treated mice. While the innate vancomycin resistance of many
lactobacilli has been well established, there have been rare reports
of resistant Lactococcus and Weissella isolates. [30,31,32] Other
differences between the gut microbial populations of these mice at
week 2 and week 8 were also apparent. These included significant
increases in the relative proportions of Bacteroidetes, Actinobac-
teria, Deferribacteres and Verrucomicrobia and a significant
decrease in the relative proportions of Firmicutes at the later time
points. The recovery of both Gram-positive (Turicibacter, Rumino-
coccaceae Incertae Sedis, Clostridium, Allobaculum and Anaeroplasma) and
Gram-negative bacteria by week 8 (Alistipes and Mucispirillum)
highlights the resilience of the gut bacteria. On the basis of PCoA
and hierarchical clustering these temporal changes seems to
represent a recovery of/development of resistance among the gut
microbiota such that it less considerably differs from that of
controls. While it is tempting to speculate that this reflects the
emergence of resistant strains from among these populations,
further investigations are required to definitively establish the basis
for this recovery. This recovery coincides with vancomycin having
a relatively less dramatic impact on weight gain by week 8 of the
study but the identity of the population that may be contributing
to this phenomenon is difficult to ascertain due to the numbers of
different taxa which are altered, however it is also apparent that
the total number of bacteria did not alter between the two time
points. These results highlight the resilience of the microbiota to
change, demonstrating that after the initial impact from vanco-
mycin they start to revert back to their original profile. This
highlights the challenge faced when utilising antimicrobials,
prebiotics, [33] microbial transplantation [34] or other interven-
tions in order to bring about long-term changes to the obesity-
associated (and other) gut microbial populations. Indeed, the
temporal resilience of the gut microbiota following exposure to
antibiotics has been highlighted in previous studies.
[14,35,36,37,38,39].
The comparison of the impact of Bac+ and Bac- on the murine
microbiota may be more revealing as a consequence of the
number of changes being fewer and the fact that the impact of
Bac+ intervention changed from being significant to non-signifi-
cant as the study continued. While previous studies with
bacteriocin-producing UCC118 strain have shown it to be active
against representatives of several Gram-positive taxa, including
Bacillus, Listeria monocytogenes, Enterococcus, Staphylococcus and Clostrid-
ium perfringens [40,41], high throughput sequencing again provided
unexpected results with respect to compositional changes, at family
level, relative to Bac- controls at week 2. Specifically a relative
reduction in the proportions of the Gram-negative families
Rikenellaceae and Porphyromonadaceae and a relative increase in the
proportions of the Gram-positive Peptococcaceae occurred. Interest-
ingly, a recent study has suggested a link between the
Porphyromonadaceae with the development of metabolic syndrome.
[42] While the decrease in weight gain observed in Bac+, relative
to Bac-, mice at week 2 and the reduction in relative numbers of
this family is notable, the proportions of this family decreased even
further in Bac+ mice by week 8 despite the fact that the impact of
the probiotic with respect to weight gain was no longer significant
by this time. Notably the proportions of Rikenellaceae, Porphyromo-
nadaceae and Peptococcaceae in Bac+ and Bac– fed mice did not differ
significantly at week 8. Further studies are needed to explore the
role these families play in the link between the gut microbial
ecosystem and obesity.
In conclusion, the data demonstrate that though vancomycin
distinctively modified the gut microbiota composition, the growth
of some bacterial families over time may be responsible for this
intervention having a less dramatic impact on weight gain by the
end of the 8 week intervention period. There also exist a number
of changes in the microbial population of animals administered
Bac+ which, if successfully targeted over a longer period, could
potentially extend the duration over which weight gain is
significantly reduced. These results provide further rationale for
altering the gut microbiota using antimicrobials but the specific
identification of the populations involved and the specificity of
action of the antimicrobials will be essential and may require
continual modification to ensure a sustained impact and to
overcome compensatory effects.
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Figure S1 Experimental design. Seven week old C57BL/J6
mice were fed a high fat or low fat diet for 20 weeks, after 12 weeks
intervention began. Sequencing was performed at intervention
week 2 and week 8 of the study.
(TIF)
Figure S2 Rarefaction curves for each group at 97%
similarity levels for intervention week 2 (A) and week 8
(B) data sets. Amount of operational taxonomic units (OUT’s)
found as a function of the number of sequence tags sampled.
(TIF)
Figure S3 Unweighted pair group method with arith-
metic mean (UPGMA) tree of all samples at both time
point’s. Highlights temporal shift and clustering by treatment
group. Vancomycin treated DIO mice present as outliers from
both time points.
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Vancomycin treatment alters gut microbiota in diet induced obese
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